| Zacks Company Profile for Regeneron Pharmaceuticals, Inc. (REGN : NSDQ) |
|
|
| |
| • Company Description |
| Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
Number of Employees: 11,851 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $731.17 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 507,904 shares |
| Shares Outstanding: 109.33 (millions) |
| Market Capitalization: $79,935.55 (millions) |
| Beta: 0.23 |
| 52 Week High: $837.55 |
| 52 Week Low: $538.01 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-3.01% |
-6.68% |
| 12 Week |
-1.69% |
-8.74% |
| Year To Date |
1.34% |
-7.82% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Leonard S. Schleifer - President; Chief Executive Officer
P. Roy Vagelos - Chair of the Board of Directors
George D. Yancopoulos - President; Chief Scientific Officer
Robert E. Landry - Executive Vice President; Finance and Chief Financ
Christopher R. Fenimore - Senior Vice President; Controller
|
|
Peer Information
Regeneron Pharmaceuticals, Inc. (CORR.)
Regeneron Pharmaceuticals, Inc. (RSPI)
Regeneron Pharmaceuticals, Inc. (CGXP)
Regeneron Pharmaceuticals, Inc. (BGEN)
Regeneron Pharmaceuticals, Inc. (GTBP)
Regeneron Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75886F107
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/02/23
|
|
Share - Related Items
Shares Outstanding: 109.33
Most Recent Split Date: (:1)
Beta: 0.23
Market Capitalization: $79,935.55 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $8.78 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $34.76 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 9.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 9.00% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/02/23 |
|
|
|
| |
